A Phase 2 interventional study of Empagliflozin and Placebo (matching empagliflozin) in Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 and Obesity, sponsored by Boehringer Ingelheim. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-24.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 1.
Among the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 2, and was the 4th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 5 · Phase 4 4
First in 2011; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 49 across the 12 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 12 have an industry lead sponsor. The 7 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 6 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
1 of the studies testing empagliflozin in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
Drug: Empagliflozin · Drug: Placebo (matching empagliflozin) · Drug: ramipril
Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.
Drug: Empagliflozin · Drug: Placebo (matching empagliflozin) · Drug: ramipril
Empagliflozin will be taken once daily
Placebo will be taken once daily
Ramipril will be taken once or twice daily
Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril.
Glomerular filtration rate (GFR) under euglycaemic conditions after 4 weeks of treatment with either empagliflozin added to ramipril or placebo added to ramipril. The pre-specified statistical analysis was not conducted, because data are too sparse in the subgroup of hyperfilterers.
Time frame: At week 4 and at week 12
Filtration Status (Glomerular Filtration Rate (GFR) < 120 mL/Min/1.73m², Yes/no) After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril
Filtration status (Glomerular Filtration Rate (GFR) \< 120 mL/min/1.73m²) after 4 weeks of treatment with either empagliflozin added to ramipril or placebo added to ramipril. Filtration status is defined as whether a patient has normal Filtration status (GFR \< mL/min/1.73m², "yes") or not (GFR ≥ mL/min/1.73m², "no"). The pre-specified statistical analysis was not conducted, because data are too sparse in the subgroup of hyperfilterers.
Time frame: At week 4 and at week 12.
A randomized, double-blinded, placebo-controlled, crossover trial to compare the effect of empagliflozin versus placebo when added to ramipril on reducing glomerular hyperfiltration in patients with type 1 Diabetes mellitus (T1D), Type 2 Diabetes (T2D), or obesity.
| Milestone | Sequence A: 25 mg Empagliflozin / Placebo | Sequence B: Placebo / 25 mg Empagliflozin |
|---|---|---|
| Started | 16 | 15 |
| Completed | 16 | 15 |
| Not completed | 0 | 0 |
| Milestone | Sequence A: 25 mg Empagliflozin / Placebo | Sequence B: Placebo / 25 mg Empagliflozin |
|---|---|---|
| Started | 16 | 15 |
| Completed | 15 | 15 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Sequence A: 25 mg Empagliflozin / Placebo | Sequence B: Placebo / 25 mg Empagliflozin |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 15 |
| Not completed | 0 | 0 |
Glomerular filtration rate (GFR) under euglycaemic conditions after 4 weeks of treatment with either empagliflozin added to ramipril or placebo added to ramipril. The pre-specified statistical analysis was not conducted, because data are too sparse in the subgroup of hyperfilterers.
| milliliter (mL) /minutes (min) /1.73m² | 25 mg Empagliflozin | Placebo |
|---|---|---|
| Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril. | 124.0 ± 10.61 | 132.5 ± 7.78 |
Filtration status (Glomerular Filtration Rate (GFR) \< 120 mL/min/1.73m²) after 4 weeks of treatment with either empagliflozin added to ramipril or placebo added to ramipril. Filtration status is defined as whether a patient has normal Filtration status (GFR \< mL/min/1.73m², "yes") or not (GFR ≥ mL/min/1.73m², "no"). The pre-specified statistical analysis was not conducted, because data are too sparse in the subgroup of hyperfilterers.
| Participants | 25 mg Empagliflozin | Placebo |
|---|---|---|
| Yes | 1 | 0 |
| No | 1 | 2 |
Collected over From drug administration until 7 days after the last dose of treatment, up to 91 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 25 mg Empagliflozin | 0/31 (0%) | 0/31 (0%) | 15/31 (48.4%) |
| Placebo | 0/30 (0%) | 2/30 (6.7%) | 13/30 (43.3%) |
| Event | 25 mg Empagliflozin | Placebo |
|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 0/31 | 1/30 |
| Testicular ruptureInjury, poisoning and procedural complications | 0/31 | 1/30 |
| Event | 25 mg Empagliflozin | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 3/31 | 7/30 |
| KetosisMetabolism and nutrition disorders | 6/31 | 1/30 |
| HeadacheNervous system disorders | 3/31 | 3/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/31 | 3/30 |
| FatigueGeneral disorders | 3/31 | 0/30 |
| ThirstGeneral disorders | 2/31 | 0/30 |
| DizzinessNervous system disorders | 2/31 | 1/30 |
Full Analysis Set (FAS): The FAS consists of all patients who were randomised, treated with at least one dose of empagliflozin/placebo and provided randomisation baseline (visit 8) and at least one post-randomisation glomerular filtration rate (GFR) measurement.
| Age, Continuous(Years) | Sequence A: 25 mg Empagliflozin / Placebo | Sequence B: Placebo / 25 mg Empagliflozin | Total |
|---|---|---|---|
| Mean | 26.5 ± 4.2 | 27.0 ± 5.0 | 26.7 ± 4.5 |
| Sex: Female, Male(Participants) | Sequence A: 25 mg Empagliflozin / Placebo | Sequence B: Placebo / 25 mg Empagliflozin | Total |
|---|---|---|---|
| Female | 10 | 7 | 17 |
| Male | 6 | 7 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Sequence A: 25 mg Empagliflozin / Placebo | Sequence B: Placebo / 25 mg Empagliflozin | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 15 | 14 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence A: 25 mg Empagliflozin / Placebo | Sequence B: Placebo / 25 mg Empagliflozin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 14 | 11 | 25 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Glomerular filtration rate (GFR) at baseline(milliliter (mL) /minutes (min) /1.73m²) | Sequence A: 25 mg Empagliflozin / Placebo | Sequence B: Placebo / 25 mg Empagliflozin | Total |
|---|---|---|---|
| Mean | 113.6 ± 9.4 | 115.7 ± 14.0 | 114.6 ± 11.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Dec 2017, 19 months.
Results were first posted in Jul 2020, 2 years 7 months after primary completion.
Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 19 months is close to that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Ramipril